Brent Furse, CEO and President

Brent Furse has served as a Director and our Chief Executive Officer and President since June 2016. Prior to coming to GeNO, Mr. Furse was a key member of the The Medicines Company leadership team where he joined in 2000 pre-IPO and served as a section 16 Officer. Held various leadership positions including Executive Vice President and Chief Commercial Officer, Vice President and General Manager Interventional Medicine, Vice President Surgery and Perioperative Care, and Vice President of Sales and Marketing. He was responsible for the launch and success of their flagship product Angiomax, and countless successful partnerships and operational excellence.  In addition to his success at The Medicines Company, Brent has held leadership positions with Centers for Disease Control, Bristol-Myers Squibb, and Schering Plough Corporation, and serves on the board of Anthera Pharmaceuticals, The Special Olympics and Salus Tele-health.


Marc Morin, Chief Financial Officer

Mr. Morin joined GeNO as CFO in October of 2017, and has more than 15 years of experience in financial and executive management at emerging growth, life sciences, and global manufacturing companies. Prior to GeNO, Mr. Morin served as the CFO of Brookhaven Medical, Inc., a privately held holding company for medical device companies and medical technologies, and as the CFO of FutureMatrix Interventional, Inc., a privately held manufacturer and producer of high pressure PTA balloon catheters and urology devices. Previously, Mr. Morin served as the Global Controller of EndoChoice Holdings (Acquired by Boston Scientific), a publicly held medical device company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. During his tenure at EndoChoice, Mr. Morin oversaw all aspects of the finance, accounting, treasury and tax functions and helped the Company raise over $200 million in debt and equity financing, including over $100 million in its initial public offering. Prior to joining EndoChoice, Mr. Morin served as the Vice President of Finance and Accounting at Case-Mate, Inc., a privately held global leader in the design and manufacture of accessories for mobile devices. During his tenure at Case-Mate, Mr. Morin led the company’s international expansion into 7 countries and distribution of products in over 76 countries worldwide. Mr. Morin began his career at KPMG where he served a number of high growth public and private companies across a wide range of industries. He received an MBA from Emory University, a Masters of Accounting degree from Georgia State University, and a Bachelor’s of Accounting degree from St. Michaels’ College. He is also a licensed CPA in the state of Georgia. 


Paul Antinori, VP, General Counsel and Secretary

Paul Antinori is the Vice President, General Counsel and Secretary of GeNO LLC. Before joining GeNO, Mr. Antinori was the principal at White Crest Consulting, a consulting firm he formed to advise clients on legal, business and public policy issues. Previously, Mr. Antinori was Senior Vice President, General Counsel and Secretary of The Medicines Company, a publicly traded global pharmaceutical company. During his tenure, the company grew from $15 million in revenue generated from one product in one country to over $700 million from multiple products sold in 25 countries around the world. Critically, Mr. Antinori led a franchise-saving lobbying and litigation strategy to restore the company’s patent on its flagship product, preserving some $2 billion in revenue. Prior to The Medicines Company, Mr. Antinori was General Counsel at Physician Computer Network, Inc., a publicly traded healthcare information technology company. Prior to his in-house positions, Mr. Antinori was a partner at the Gibbons law firm in Newark, NJ and, before Gibbons, at other major law firms in New York and New Jersey. Mr. Antinori received his J.D. from the University of Virginia School of Law and his B.A. from Boston College (Summa Cum Laude; Phi Beta Kappa). He is a member of the Board of Directors of R.F. Madison Co., a specialty retailer, and a member of the Advisory Board of the Gibbons Institute of Law, Science and Technology at Seton Hall Law School in Newark, NJ. Mr. Antinori has been recognized by Inside Jersey magazine as one of New Jersey’s Top Legal Minds. 


Tod Shultz, Chief Strategy Officer

As Head of Strategy and New Business Development, Tod brings a unique ability to create and simplify complex programs into actionable high-impact plans. Tod is an entrepreneurial leader with broad expertise and experience in the acute care hospital and surgical markets. In his 27 years within the medical device and biopharmaceutical industry he has built and led numerous high impact and innovative programs leading to significant business expansion, growth and profit. Tod has held leadership roles in general management, strategy, new business development, marketing and product development within Fortune 500 corporations, mid-sized and start-up companies including Covidien’s Surgical Business Unit, Kimberly-Clark Health Care, TECNOL, Johnson & Johnson Medical and The Medicines Company. Tod holds a BS in Mechanical Engineering from the University of Texas at Arlington, and has continuously expanded his marketing and leadership skills through executive education programs including Harvard Business School and Yale School of Management.


Namita Khanna, Executive Director Strategic Development

Namita is a successful senior-level business leader driving more than two decades of exceptional results focused on sales, business development, and account management across diverse markets including healthcare, finance, and hospitality.  She is strategic and multidisciplinary with an eye for innovation, positioning, and relevance.  She has worked for a wide array of Fortune 500 firms such as American Express, Marriott International, and Eli Lilly and Company.

Namita attended Widener University in Philadelphia obtaining an undergraduate degree in Hospitality Management and Marketing. Following an International feasibility project, she began her career in the Marriott Executive Sales Training Program working in New York and the Washington DC area. Namita then went back to school for Investment education and received her Series 6, 7, 63, 65, and all relevant financial licenses to begin working as a Financial Investment Planner with American Express in Washington DC and then Atlanta.  After starting and working in a successful group practice in Atlanta, she transitioned to the Pharmaceutical Industry and worked in hospitals and institutions for 17 years from New Jersey, to Atlanta, to Orlando for Eli Lilly and Company. After a three-year period with an acute care hospital-based company named The Medicines Company, Namita created her own consulting firm and is currently working as Executive Director Strategic Development for GeNO.


Ray Russo, VP, Commercialization

Ray Russo is a seasoned pharmaceutical executive with over 30 years of industry experience, including senior positions in global marketing, sales, pricing & reimbursement, and finance.  He most recently held the role of Senior Vice President Global Acute Cardiovascular Care at The Medicines Company, an acute care specialty company.  Prior to joining MDCO, he was the Chief Commercial Officer at Prism Pharmaceuticals, a specialty biotech company where he not only led the preparation for launch of their primary drug, but also crafted and led presentations to Wall Street and industry leaders, resulting in the sale of the company to Baxter International in 2011.  Ray came to Prism from Shionogi Pharma, Inc., where he served as Vice President of Sales/Marketing, and where he successfully executed a number of product launches.  He began his career at Schering-Plough Corp., where he led a number of highly successful global product launches in both the specialty and primary care areas, most recently serving as Global Vice President, Cardiovascular Products.  He has extensive partnering experience with both large pharma (eg; Vytorin/Zetia, Merck, Brilinta/Astra Zenca); as well as emerging biotech companies (eg; Integrilin, Cor Therapeutics).  Ray previously sat on the Duke Fuqua Business School Health Sector Advisory Board and was formerly a board member and chairman of the NJ Epilepsy Foundation/Family Resource Network.  He holds a BA in Economics and an MBA in Accounting from Rutgers University and holds a CPA (inactive) in the state of NJ.